Tatva Chintan Pharma Chem · NSE: TATVA · BSE: 543321
Q1 FY24 results · Apr–Jun 2023
Tatva Chintan Pharma Chem reported revenue from operations of ₹114.36 crore (up 29.4% from Q1 FY23) and net profit of ₹9.50 crore (down 3.0% from Q1 FY23) for Q1 FY24 (Apr–Jun 2023), on a consolidated basis.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 114.36 | 88.40 | +29.4% | 124.51 | −8.1% |
| Other income | 1.01 | 1.83 | −44.5% | 0.84 | +20.1% |
| Total income | 115.38 | 90.23 | +27.9% | 125.36 | −8.0% |
| Profit before tax | 13.42 | 13.70 | −2.0% | 7.80 | +72.0% |
| Net profit for the period | 9.50 | 9.80 | −3.0% | 16.95 | −43.9% |
| EPS, basic (₹) | 4.29 | 4.42 | −2.9% | 7.65 | −43.9% |
| Net margin (%) | 8.3 | 11.1 | 13.6 |
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 106.11 | 86.06 | +23.3% | 119.41 | −11.1% |
| Other income | 1.01 | 1.83 | −44.5% | 0.78 | +29.6% |
| Total income | 107.12 | 87.89 | +21.9% | 120.19 | −10.9% |
| Profit before tax | 11.72 | 11.98 | −2.1% | 6.89 | +70.1% |
| Net profit for the period | 8.25 | 8.50 | −3.0% | 16.15 | −48.9% |
| EPS, basic (₹) | 3.72 | 3.83 | −2.9% | 7.29 | −49.0% |
| Net margin (%) | 7.8 | 9.9 | 13.5 |
Consolidated
- Filed with BSE
- 04 Aug 2023, 19:49 IST
- Board meeting
- 04 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 04 Aug 2023, 19:49 IST
- Board meeting
- 04 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE